Abstract
UCSF researchers have developed a platform capable of producing mAbs that target post-translational modifications such as phosphorylation. The technology could open up a host of new targets for cancer and other diseases associated with aberrant modifications. Next, the team will have to show that the mAbs target endogenous proteins in vivo.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have